BridgeBio Pharma (BBIO) Income towards Parent Company (2018 - 2026)

BridgeBio Pharma has disclosed Income towards Parent Company across 9 years of filings, most recently posting -$112.7 million for Q1 2026.

• Income towards Parent Company for Q1 2026 came in at -$112.7 million, up 3.81% year-over-year; the trailing twelve-month figure through Mar 2026 was -$676.0 million (down 8.29% YoY), and the FY2025 annual result was -$732.9 million, down 34.89% from the prior year.
• Income towards Parent Company came in at -$112.7 million for Q1 2026 at BridgeBio Pharma, up from -$194.6 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$19.1 million in Q1 2024 to a low of -$267.4 million in Q4 2024.
• The 5-year median for Income towards Parent Company is -$162.2 million (2023), against an average of -$151.5 million.
• Across the five-year window, Income towards Parent Company soared 86.59% in 2024 and tumbled 514.64% in 2025, its largest moves.
• BridgeBio Pharma's Income towards Parent Company stood at -$145.1 million in 2022, then slumped by 32.37% to -$192.1 million in 2023, then sank by 39.19% to -$267.4 million in 2024, then rose by 27.21% to -$194.6 million in 2025, then jumped by 42.12% to -$112.7 million in 2026.
• The last three Income towards Parent Company figures came in at -$112.7 million (Q1 2026), -$194.6 million (Q4 2025), and -$185.0 million (Q3 2025), per Business Quant data.